UroGen Pharma Ltd. (URGN) Income Statement
URGN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsURGN revenue and net income
Where URGN's revenue goes
2025Each bar shows an amount and its share of revenue. URGN kept −139.8% of revenue as net income.
URGN profit margins
URGN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +21.4% | +19.5% | +56.2% | — |
| Gross profit | +19.4% | +19.7% | +55.3% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
URGN quarterly EPS vs estimates
UroGen Pharma beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $0.38).
URGN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18,000 | $1.1M | $8.2M | $17.5M |
| Cost of revenue | $12.4M | $8.9M | $9.4M | $7.7M | $5.2M | $1.0M | $48,000 | $1.8M | $600,000 | $28,000 |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M | $10.8M | $18,000 | −$675,000 | $7.6M | $17.5M |
| Research & development | $67.1M | $57.1M | $45.6M | $52.9M | $47.6M | $47.3M | $49.3M | $36.9M | $18.7M | $10.3M |
| Sales, general & admin | $155.1M | $121.2M | $90.4M | $82.8M | $87.5M | $90.2M | $60.2M | $39.6M | $8.8M | $6.4M |
| Total operating expenses | $222.2M | $178.3M | $138.9M | $135.7M | $135.2M | $137.5M | $109.5M | $76.5M | $27.5M | $16.7M |
| Operating income | −$124.9M | −$96.8M | −$65.5M | −$79.0M | −$92.3M | −$126.7M | −$109.5M | −$77.2M | −$19.9M | $798,000 |
| Interest income | $6.0M | $8.9M | $2.4M | $938,000 | $365,000 | $2.0M | $4.6M | $1.9M | $31,000 | $2.7M |
| Interest expense | $33.8M | $12.5M | $14.7M | $8.4M | $17.4M | $3.7M | $284,000 | $0 | $0 | $0 |
| Income before taxes | −$153.4M | −$124.0M | −$98.3M | −$108.0M | −$109.4M | −$125.1M | −$105.1M | −$75.5M | −$20.0M | −$1.9M |
| Income taxes | $78,000 | $2.8M | $3.9M | $1.8M | $1.4M | $3.4M | −$4.6M | $125,000 | $19,000 | $0 |
| Net income | −$153.5M | −$126.9M | −$102.2M | −$109.8M | −$110.8M | −$128.5M | −$105.1M | −$75.7M | −$20.0M | −$1.9M |
| EBITDA | −$135.7M | −$94.5M | −$60.4M | −$76.2M | −$107.6M | −$124.7M | −$108.2M | −$76.8M | −$19.7M | $1.0M |
| EPS (diluted) | −$3.19 | −$3.23 | −$3.73 | −$4.78 | −$4.96 | −$5.92 | −$5.11 | −$4.76 | −$2.55 | −$0.18 |
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | 100.0% | −59.8% | 92.6% | 99.8% |
| Operating margin | −113.7% | −107.1% | −79.2% | −122.8% | −192.1% | −1,074.2% | −608,211.1% | −6,842.2% | −244.5% | 4.6% |
| Net margin | −139.8% | −140.4% | −123.6% | −170.6% | −230.7% | −1,088.9% | −584,144.4% | −6,707.2% | −245.2% | −11.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.5M | $51.0M | $37.8M | $27.5M | $24.2M | $20.3M | $24.6M | $25.2M | $21.8M | $18.8M | $23.5M | $20.9M |
| Cost of revenue | $6.6M | $4.1M | $3.3M | $3.3M | $3.5M | $2.3M | $2.5M | $2.5M | $2.2M | $1.7M | $2.3M | $2.4M |
| Gross profit | $65.9M | $46.8M | $34.5M | $24.2M | $20.7M | $17.9M | $22.1M | $22.8M | $19.6M | $17.1M | $21.2M | $18.5M |
| Research & development | $17.3M | $15.6M | $14.3M | $14.0M | $18.9M | $19.9M | $14.9M | $11.4M | $15.4M | $15.5M | $11.3M | $10.2M |
| Sales, general & admin | $48.4M | $51.5M | $39.3M | $37.6M | $43.2M | $35.0M | $34.9M | $28.9M | $30.1M | $27.3M | $24.6M | $21.8M |
| Total operating expenses | $65.8M | $67.1M | $53.7M | $51.6M | $62.1M | $54.8M | $49.8M | $40.3M | $45.5M | $42.8M | $35.9M | $32.0M |
| Operating income | $111,000 | −$20.3M | −$19.1M | −$27.4M | −$41.4M | −$36.9M | −$27.7M | −$17.5M | −$25.8M | −$25.7M | −$14.6M | −$13.5M |
| Interest income | $946,000 | $931,000 | $908,000 | $1.2M | $1.7M | $2.2M | $2.8M | $2.8M | $1.7M | $1.8M | $726,000 | $835,000 |
| Interest expense | $4.9M | $8.7M | $13.0M | $8.0M | $8.8M | $4.1M | $3.9M | $2.7M | $3.5M | $2.4M | $3.6M | $3.8M |
| Income before taxes | −$8.7M | −$28.3M | −$26.6M | −$34.4M | −$48.9M | −$43.5M | −$34.9M | −$23.6M | −$33.4M | −$32.2M | −$22.2M | −$21.9M |
| Income taxes | $5.6M | −$4.8M | −$275,000 | −$1.1M | $1.0M | $392,000 | $2.6M | $91,000 | $38,000 | $54,000 | $3.9M | −$9,000 |
| Net income | −$14.4M | −$23.6M | −$26.4M | −$33.3M | −$49.9M | −$43.8M | −$37.5M | −$23.7M | −$33.4M | −$32.3M | −$26.0M | −$21.9M |
| EBITDA | −$3.2M | −$19.0M | −$22.2M | −$25.8M | −$48.8M | −$38.9M | −$26.3M | −$14.7M | −$29.6M | −$23.8M | −$7.4M | −$12.2M |
| EPS (diluted) | −$0.28 | −$0.47 | −$0.53 | −$0.69 | −$1.05 | −$0.92 | −$0.80 | −$0.55 | −$0.91 | −$0.97 | −$0.72 | −$0.68 |
| Gross margin | 90.9% | 91.9% | 91.3% | 88.1% | 85.3% | 88.5% | 89.9% | 90.3% | 89.8% | 90.8% | 90.3% | 88.6% |
| Operating margin | 0.2% | −39.8% | −50.5% | −99.7% | −171.2% | −182.3% | −112.6% | −69.6% | −118.3% | −137.1% | −62.1% | −64.7% |
| Net margin | −19.8% | −46.3% | −69.7% | −121.3% | −206.2% | −216.5% | −152.7% | −93.9% | −152.9% | −171.9% | −110.6% | −104.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in URGN's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
URGN financial results
In fiscal year 2025 (ended December 31, 2025), UroGen Pharma reported revenue of $109.8 million, up 21.4% from the year before. It had a net loss of $153.5 million, a net profit margin of −139.8%. Diluted earnings per share came to −$3.19. Over five years revenue grew at an average rate of 56.2% a year.
See the URGN stock overview for the latest quote and news, or the URGN chart for price history and technical indicators.
URGN income statement FAQ
What is UroGen Pharma's annual revenue?
UroGen Pharma reported total revenue of $109.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 21.4% from $90.4 million the previous year.
Is UroGen Pharma profitable?
No. UroGen Pharma reported a net loss of $153.5 million in fiscal 2025, a net profit margin of −139.8%; its operating margin was −113.7%.
What is UroGen Pharma's gross margin?
UroGen Pharma's gross margin was 88.7% in fiscal 2025: for every $100 of revenue, UroGen Pharma kept $89 after the direct cost of its products and services.
How much does UroGen Pharma spend on research and development?
UroGen Pharma spent $67.1 million on research and development in fiscal 2025, 61.1% of revenue.
How fast is UroGen Pharma growing?
Revenue grew 56.2% a year on average over the last five fiscal years, from $11.8 million to $109.8 million.
What are UroGen Pharma's earnings per share?
UroGen Pharma earned $-3.19 per diluted share in fiscal 2025, compared with $-3.23 a year earlier.
When will UroGen Pharma report its next earnings?
UroGen Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does UroGen Pharma's fiscal year end?
UroGen Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.